ClearPoint Neuro, Inc.
NASDAQ:CLPTMedical - Devices
+$0.89 today
- Market cap
- $247.14M
- Beta
- 1.31
- P/E (TTM)
- -18.0
- EPS (TTM)
- -$0.98
Volume 0.64M
Average 0.67M
CLPT Depreciation & Amortization
Non-cash expense that spreads the cost of physical and intangible assets over their useful lives.
ClearPoint Neuro, Inc.NASDAQ: CLPT
Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026
Depreciation & amortization growth accelerates
Q1 FY2026 depreciation & amortization of $1.11M rose 233.2% year over year, ahead of the +50.7% change in trailing-twelve-month depreciation & amortization. Sequentially, it rose 30.8% from the prior quarter. Over 3 fiscal years it compounded at +42.3% a year.
Context
- Depreciation & amortization amounted to 6.1% of revenue in FY2025, unchanged from a year earlier.
- Depreciation & amortization increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +233.2% holds above the trailing-twelve-month pace of +50.7%.
Sources:Income StatementText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the income statement
- Latest · FY2025
- 2.24M USD
- Year-over-year change
- +17.6%
- 4-year CAGR
- +34.1%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 2.24M | +17.6% |
| FY2024 | 2024-12-31 | 1.9M | +30.6% |
| FY2023 | 2023-12-31 | 1.46M | +87.5% |
| FY2022 | 2022-12-31 | 777K | +12.3% |
| FY2021 | 2021-12-31 | 692K | — |
Depreciation & Amortization vs competitors
How CLPT compares with its peers on the latest reported figures
- Peers report in different currencies, so depreciation & amortization is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +50.7% is the 2nd highest of 10, against a peer median of -0.7%.
- Depreciation & amortization amounts to 6.5% of revenue for CLPT, versus a peer median of 5.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $135.37M USD | +42.0% | +16.7% | 16.4% | |
| LTM Mar 2026 | CA$56.2M CAD | -0.2% | +5.9% | 6.0% | |
| LTM Mar 2026 | $39.5M USD | -9.6% | -11.0% | 5.5% | |
| LTM Apr 2026 | $27.1M USD | -0.7% | -6.8% | 3.2% | |
| LTM Mar 2026 | $11.9M USD | +9.1% | +28.4% | 5.8% | |
| LTM Mar 2026 | $8.15M USD | +78.5% | -7.6% | 4.0% | |
| LTM Mar 2026 | $6.29M USD | -60.3% | -22.5% | 7.3% | |
| LTM Mar 2026 | $2.66M USD | +50.7% | +42.3% | 6.5% | |
| LTM Mar 2026 | $1.28M USD | -95.5% | -67.7% | 0.6% | |
| LTM Mar 2026 | $179K USD | -14.4% | -13.2% | — | |
| Peer median (excluding CLPT) | — | -0.7% | -7.6% | 5.7% | |
Competitors are the stored peer set for CLPT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 16.3M | 20.55M | 23.96M | 31.39M | 36.97M |
| Cost of Revenue | 5.18M | 7.02M | 10.34M | 12.27M | 14.28M |
| Gross Profit | 11.12M | 13.53M | 13.61M | 19.12M | 22.69M |
| Gross Margin | 68.2% | 65.8% | 56.8% | 60.9% | 61.4% |
| Research & Development | 9.28M | 10.89M | 11.71M | 12.39M | 13.9M |
| Selling, General & Admin | 15.22M | 18.97M | 24.35M | 26.48M | 32.96M |
| Operating Expenses | 24.5M | 29.86M | 36.06M | 38.87M | 46.86M |
| Depreciation & Amortization | 692K | 777K | 1.46M | 1.9M | 2.24M |
| EBITDA | (12.75M) | (15.58M) | (20.63M) | (17.01M) | (20.86M) |
| EBITDA Margin | -78.2% | -75.8% | -86.1% | -54.2% | -56.4% |
| Operating Income | (13.37M) | (16.33M) | (22.45M) | (19.75M) | (24.16M) |
| Operating Margin | -82.1% | -79.5% | -93.7% | -62.9% | -65.4% |
| Interest Income | 0 | 0 | 386K | 872K | 1.21M |
| Interest Expense | 973K | 81K | 0 | 0 | 2.39M |
| Other Income / Expenses | (1.04M) | (103K) | 357K | 832K | (1.32M) |
| Income Before Tax | (14.41M) | (16.44M) | (22.09M) | (18.91M) | (25.49M) |
| Pre-Tax Margin | -88.4% | -80.0% | -92.2% | -60.3% | -68.9% |
| Income Tax Expense | 0 | 0 | 0 | 0 | 55K |
| Net Income | (14.41M) | (16.44M) | (22.09M) | (18.91M) | (25.54M) |
| Net Margin | -88.4% | -80.0% | -92.2% | -60.3% | -69.1% |
| EPS (Basic) | (0.69) | (0.68) | (0.90) | (0.70) | (0.90) |
| EPS (Diluted) | (0.69) | (0.68) | (0.90) | (0.70) | (0.90) |
| Weighted Avg Shares | 20.73M | 24.18M | 24.61M | 27.03M | 28.32M |
| Weighted Avg Shares (Diluted) | 20.73M | 24.18M | 24.61M | 27.03M | 28.32M |
ClearPoint Neuro, Inc.
NASDAQ:CLPT
Intrinsic Alpha fair value
Locked
Current Price
$7.71
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.